Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: A case-control study

Schizophrenia Research

Volumn 141, Issue 2-3, 2012, Pages 173-178

  Ronaldson, Kathlyn J ^a   Fitzgerald, Paul B ^b   Taylor, Andrew J ^c   Topliss, Duncan J ^c   Wolfe, Rory ^a   McNeil, John J ^a  

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

Case control study; Clozapine; Drug hypersensitivity reaction; Myocarditis; Risk factors; Schizophrenia

Indexed keywords

CLOZAPINE; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ALCOHOL ABUSE; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENTIATION; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYOCARDITIS; PATIENT MONITORING; PHENOTYPE; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING; SUBSTANCE ABUSE; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BODY MASS INDEX; CASE-CONTROL STUDIES; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDITIS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TIME FACTORS; VALPROIC ACID; YOUNG ADULT;

EID: 84866908977     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.08.018     Document Type: Article

References (26)

1. Brownlowe K., Sola C. Clozapine toxicity in smoking cessation and with ciprofloxacin. Psychosomatics 2008, 49(2):176.
2. Chung W.H., Hung S.I., Hong S.H., Hsih M.S., Yang L.C., Ho H.C., et al. A marker for Stevens Johnson syndrome. Nature 2004, 428(6982):486.
3. Couchman L., Morgan P.E., Spencer E.P., Flanagan R.J. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007. Ther. Drug Monit. 2010, 32(4):438-447.
4. Daly A.K., Donaldson P.T., Bhatnagar P., Shen Y., Pe'er I., Floratos A., et al. HLA-B 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 2009, 41(7):816-819.
5. Degner D., Bleich S., Grohmann R., Bandelow B., Rüther E. Myocarditis associated with clozapine treatment. Aust. N. Z. J. Psychiatry 2000, 34(5):880.
6. Devarajan S., Kutcher S.P., Dursun S.M. Clozapine and sudden death. Lancet 2000, 355(9206):841.
7. Diaz F.J., Santoro V., Spina E., Cogollo M., Rivera T.E., Botts S., de Leon J. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 2008, 41(3):81-91.
8. Fairley C.K., McNeil J.J., Desmond P., Smallwood R., Young H., Forbes A. Risk factors for development of flucloxacillin associated jaundice. BMJ 1993, 306(6872):233-235.
9. GlaxoSmithKline Australia Pty Ltd. Lamictal (Lamotrigine) product information Internet:, (Accessed 30 August 2011). https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04710-3.
10. Haas S.J., Hill R., Krum H., Liew D., Tonkin A., Demos L., et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf. 2007, 30(1):47-57.
11. Hägg S., Spigset O., Bate A., Söderström T.G. Myocarditis related to clozapine treatment. J. Clin. Psychopharmacol. 2001, 21(4):382-388.
12. Haslemo T., Eikeseth P.H., Tanum L., Molden E., Refsum H. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur. J. Clin. Pharmacol. 2006, 62(12):1049-1053.
13. Hung S.I., Chung W.H., Liou L.B., Chu C.C., Lin M., Huang H.P., et al. HLA-B 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(11):4134-4139.
14. Kilian J.G., Kerr K., Lawrence C., Celermajer D.S. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999, 354(9193):1841-1845.
15. La Grenade L., Graham D., Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N. Engl. J. Med. 2001, 345(3):224.
16. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373(9657):31-41.
17. Mallal S., Phillips E., Carosi G., Molina J.M., Workman C., Tomazic J., et al. HLA-B 5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 2008, 358(6):568-579.
18. Merrill D.B., Dec G.W., Goff D.C. Adverse cardiac effects associated with clozapine. J. Clin. Psychopharmacol. 2005, 25(1):32-41.
19. Reinders J., Parsonage W., Lange D., Potter J.M., Plever S. Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust. N. Z. J. Psychiatry 2004, 38(11-12):915-922.
20. Ronaldson K.J., McNeil J.J. Improving drug safety by locating genetic markers for hypersensitivity reactions. Med. J. Aust. 2009, 190(11):641-643.
21. Ronaldson K.J., Taylor A.J., Fitzgerald P.B., Topliss D.J., Elsik M., McNeil J.J. Diagnostic characteristics of clozapine induced myocarditis identified by an analysis of 38 cases and 47 controls. J. Clin. Psychol. 2010, 71(8):976-981.
22. Ronaldson K.J., Taylor A.J., Fitzgerald P.B., Topliss D.J., McNeil J.J. Clinical course and analysis of ten fatal cases of clozapine-induced myocarditis and comparison with 66 surviving cases. Schizophr. Res. 2011, 128(1-3):161-165.
23. Ronaldson K.J., Taylor A.J., Fitzgerald P.B., Topliss D.J., McNeil J.J. A new monitoring protocol for clozapine induced myocarditis based on an analysis of 75 cases and 94 controls. Aust. N. Z. J. Psychiatry 2011, 45(6):458-465.
24. Sanofi-Aventis Australia Pty Ltd. Epilim (sodium valproate) product information Internet:, (Accessed 30 August 2011). https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-05620-3.
25. Tiihonen J., Lonnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A. 11-Year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374(9690):620-627.
26. Tirupati S. Clozapine and heart in the Hunter region. Aust. N. Z. J. Psychiatry 2006, 40(1):97.